ENLIGHTEN (PROTOCOL NUMBER: RPC-1063-MS-001)

ENLIGHTEN

Objective

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)

The MS Center at EvergreenHealth is conducting an open-label study in subjects with Relapsing Multiple Sclerosis (RMS) treated with ozanimod HCl.

Who may be eligible to participate?

Male or female patients, age 18 to 65 years (inclusive) who have been diagnosed with RMS within 5 years of Screening. Other inclusion/exclusion criteria apply.

What does participation involve?

All subjects will receive orally administered ozanimod HCl 1 mg. Subjects must have been diagnosed with RMS within 5 years of study entry. The treatment period is 36 months. For subjects who discontinue the study, there will be a 30-day (± 15 days) and a 90-day (± 10 days) Safety Follow-up Visit.

Investigator

Virginia I. Simnad, MD, MSc, EvergreenHealth MS Center

Clinical Trial Categories

• Multiple Sclerosis

Contact

EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com